Point-of care Microfluidics for Early Detection of Cancer

用于癌症早期检测的护理点微流控

基本信息

  • 批准号:
    8999413
  • 负责人:
  • 金额:
    $ 172.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Early cancer detection is not only critical in providing curative therapies for the vast majority of solid malignancies and preventing mortality, but also reducing morbidity and costs. However, most existing strategies for early detection suffer from poor specificity: they are as likely to cause complications and deaths from false positives or overdiagnosis of non-invasive cancers as they are from identifying true cancers at an early stage. Recent data from our own group and others show that Circulating Tumor Cells (CTCs) may be shed in significant numbers into the blood stream of patients with invasive but localized and early-stage cancers. These observations suggest that, rather than being a rare and late event in the evolution of cancer, the presence of CTCs may be an early herald of tumor vascular invasion, preceding a considerable period of time for the eventual establishment of viable distant metastases. Our specific strategy is to develop a highly sensitive digital readout based on RNA in CTCs using the microfluidic CTC isolation approach (CTC-iChip) combined with digital droplet RNA (ddPCR) measurement platform. It is important to note that the CTC-iChip is unique in that it makes no a priori assumption about the type of the tumor cells and as such it applies to all cancers. Detecting tumor lineage specific RNA within noninvasively accessed tumor cells is the technology most likely to be not only highly specific and sensitive but also universal for early detection of invasive cancer. To this end, we have 3 distinct but interrelated Aims. In Aim I, we will integrate CTC-iChip and digital droplet PCR to develop a highly specific and sensitive RNA-iChip. In Aim II, we will select two cancers for which sensitive but nonspecific screening tests are currently available, prostate and lung cancer, and we propose to transform these into robust and reliable tests using RNA-iChip that would enable broad screening for invasive and curable cancers. In Aim III, we propose to develop the point of care RNA-iChip broad dissemination beyond academic medical centers to local hospitals, oncology clinics and to physicians' offices. Success with prostate and lung cancers would have a profound impact in decreasing cancer morbidity and mortality, and open a path toward broad-based early detection of multiple cancers.
 描述(申请人提供):早期癌症检测不仅在为绝大多数实体恶性肿瘤提供根治疗法和防止死亡方面至关重要,而且还可以降低发病率和成本。然而,大多数现有的早期检测策略都存在较低的特异性:它们与在早期阶段识别真实癌症一样可能导致非浸润性癌症的假阳性或过度诊断而导致并发症和死亡。来自我们自己的小组和其他人的最新数据表明,循环中的肿瘤细胞(CTC)可能大量进入侵袭性但局限性的早期癌症患者的血流中。这些观察结果表明,在癌症的发展过程中,CTC的存在并非罕见的晚期事件,而可能是肿瘤血管侵犯的早期预兆,为最终建立可行的远处转移提供了相当长的一段时间。我们的具体战略是使用微流控CTC分离方法(CTC-iChip)结合数字液滴RNA(DdPCR)测量平台开发基于CTC中RNA的高灵敏度数字读数。值得注意的是,CTC-iChip是独一无二的,因为它没有关于肿瘤细胞类型的先验假设,因此它适用于所有癌症。在非侵袭性获取的肿瘤细胞中检测肿瘤谱系特异性RNA是最有可能是最具特异性和敏感性的技术,也是最有可能普遍用于早期检测侵袭性癌症的技术。为此,我们有三个截然不同但相互关联的目标。在目标一中,我们将CTC-iChip与数字液滴聚合酶链式反应相结合,开发出一种高度特异和灵敏的RNA-iChip。在AIM II中,我们将选择两种目前可用于敏感但非特异性筛查测试的癌症:前列腺癌和肺癌,我们建议使用RNA-iChip将这些测试转变为可靠的测试,从而能够对侵袭性和可治愈癌症进行广泛筛查。在AIM III中,我们建议开发护理点RNA-iChip,将其广泛传播到学术医疗中心以外的地方医院、肿瘤学诊所和医生办公室。前列腺癌和肺癌的成功将对降低癌症发病率和死亡率产生深远影响,并为广泛早期发现多种癌症开辟道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel A. Haber其他文献

En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition
  • DOI:
    10.1016/j.trecan.2015.07.006
  • 发表时间:
    2015-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Nicola Aceto;Mehmet Toner;Shyamala Maheswaran;Daniel A. Haber
  • 通讯作者:
    Daniel A. Haber
Targeting von humanem satellit ii (hsatii)
瞄准 von humanem satellit ii (hsatii)
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Naar;Mihir S. Rajurkar;David T. Ting;Daniel A. Haber;Shyamala Maheswaran;Francesca Bersani
  • 通讯作者:
    Francesca Bersani
Deploying blood-based cancer screening
部署基于血液的癌症筛查
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    56.9
  • 作者:
    D. Micalizzi;L. Sequist;Daniel A. Haber
  • 通讯作者:
    Daniel A. Haber
Wilms' tumour: connecting tumorigenesis and organ development in the kidney
肾母细胞瘤:连接肾脏肿瘤发生与器官发育
  • DOI:
    10.1038/nrc1696
  • 发表时间:
    2005-08-19
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Miguel N. Rivera;Daniel A. Haber
  • 通讯作者:
    Daniel A. Haber
Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
表皮生长因子受体突变在预测非小细胞肺癌靶向药物敏感性或耐药性中的作用。
  • DOI:
    10.1016/s1525-7304(11)70363-1
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    G. K. Reddy;Daniel A. Haber;Chandra P. Belani
  • 通讯作者:
    Chandra P. Belani

Daniel A. Haber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel A. Haber', 18)}}的其他基金

Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy
从白细胞分离术产品中对肺癌细胞进行微流体分选,作为转移性肿瘤活检的替代方法
  • 批准号:
    10673075
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
白细胞分离血液制品的高流量微流体用于乳腺循环肿瘤细胞的功能分析
  • 批准号:
    10544808
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy
从白细胞分离术产品中对肺癌细胞进行微流体分选,作为转移性肿瘤活检的替代方法
  • 批准号:
    10199185
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
白细胞分离血液制品的高流量微流体用于乳腺循环肿瘤细胞的功能分析
  • 批准号:
    10327299
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy
从白细胞分离术产品中对肺癌细胞进行微流体分选,作为转移性肿瘤活检的替代方法
  • 批准号:
    10455704
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation
微循环中循环肿瘤细胞簇的转移和生物物理学
  • 批准号:
    9924267
  • 财政年份:
    2018
  • 资助金额:
    $ 172.16万
  • 项目类别:
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation
微循环中循环肿瘤细胞簇的转移和生物物理学
  • 批准号:
    10429911
  • 财政年份:
    2018
  • 资助金额:
    $ 172.16万
  • 项目类别:
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation
微循环中循环肿瘤细胞簇的转移和生物物理学
  • 批准号:
    10152522
  • 财政年份:
    2018
  • 资助金额:
    $ 172.16万
  • 项目类别:
P1 - Clinical Correlations of WTX Inactivation in Wilms Tumor
P1 - 肾母细胞瘤中 WTX 失活的临床相关性
  • 批准号:
    8079677
  • 财政年份:
    2010
  • 资助金额:
    $ 172.16万
  • 项目类别:
Data Production, and Informatics and Integration
数据生产、信息学和集成
  • 批准号:
    8125843
  • 财政年份:
    2010
  • 资助金额:
    $ 172.16万
  • 项目类别:

相似海外基金

Systems modeling to address the social and biological drivers of disparities in infection and mortality from emerging infectious diseases
用于解决新发传染病感染和死亡率差异的社会和生物驱动因素的系统建模
  • 批准号:
    10669177
  • 财政年份:
    2022
  • 资助金额:
    $ 172.16万
  • 项目类别:
Systems modeling to address the social and biological drivers of disparities in infection and mortality from emerging infectious diseases
用于解决新发传染病感染和死亡率差异的社会和生物驱动因素的系统建模
  • 批准号:
    10415713
  • 财政年份:
    2022
  • 资助金额:
    $ 172.16万
  • 项目类别:
Transporting established insights from classical experimental design to address causal questions in environmental epidemiology including the understanding of biological mediating mechanisms
运用经典实验设计的既定见解来解决环境流行病学中的因果问题,包括对生物介导机制的理解
  • 批准号:
    10395286
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Advancing cryo-EM technology to address difficult biological questions
推进冷冻电镜技术解决棘手的生物学问题
  • 批准号:
    10570241
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Advancing cryo-EM technology to address difficult biological questions
推进冷冻电镜技术解决棘手的生物学问题
  • 批准号:
    10166355
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Advancing cryo-EM technology to address difficult biological questions
推进冷冻电镜技术解决棘手的生物学问题
  • 批准号:
    10376252
  • 财政年份:
    2021
  • 资助金额:
    $ 172.16万
  • 项目类别:
Building Infrastructure to Address Social, Cultural and Biological Determinants of Diabetes in Lebanon
建设基础设施以解决黎巴嫩糖尿病的社会、文化和生物决定因素
  • 批准号:
    10237378
  • 财政年份:
    2020
  • 资助金额:
    $ 172.16万
  • 项目类别:
Reprogramming genetic information at the RNA level: optimizing tools to address specific biological questions
在 RNA 水平上重新编程遗传信息:优化工具来解决特定的生物学问题
  • 批准号:
    404867268
  • 财政年份:
    2018
  • 资助金额:
    $ 172.16万
  • 项目类别:
    Priority Programmes
Biological soil crusts as unique microecosystem represent a suitable model system to address taxonomy and cryptic diversity of microalgal key players
生物土壤结皮作为独特的微生态系统,代表了解决微藻关键参与者的分类学和神秘多样性的合适模型系统
  • 批准号:
    350173788
  • 财政年份:
    2017
  • 资助金额:
    $ 172.16万
  • 项目类别:
    Priority Programmes
Multidisciplinary translational research to address social disparities in osteoporosis: Understanding the social context of biological mechanisms
解决骨质疏松症社会差异的多学科转化研究:了解生物机制的社会背景
  • 批准号:
    nhmrc : 1107510
  • 财政年份:
    2016
  • 资助金额:
    $ 172.16万
  • 项目类别:
    Career Development Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了